Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06580860
Recruiting Observational

Psychiatric Multi-omics and Neuroimaging Project

NCT06580860 · tracked via the Priya Life Science China tracker
Sponsor
mingjun Zhong
Phase
Observational
Started
2016-01
Last updated
2026-03-13

Condition(s) studied

Mental DisordersHealthy Control

Investigational drug(s) / intervention(s)

Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids

Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids: Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.

Study summary

This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.

Eligibility

Sex
ALL
Min age
13 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age) * Course of disease: \<24 months * Priority is given to patients who have never taken medicine or duration of drug use \< 2 weeks * No nuclear magnetic contraindications. Exclusion Criteria: * Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence * Have a major physical disease or infectious disease * History of coma and serious neurological disease 4.MRI contraindications.

Primary outcome measure(s)

  • cortical morphology — 40 minutes
    Data were obtained using magnetic resonance scans
  • target gene charaacteristics — 1 day
    10ml peripheral blood was extracted for gene analysis
  • scale scores — 90 minutes.
    The score of each dimension and the total score were calculated according to the scale.The scale includes three dimensions: negative symptom, positive symptom and general psychopathology, and the score range of each dimension is different. The total score ranges from 30 to 210, with higher scores indicating worse results.

Trial sites (1)

FacilityCityRegionStatus
The Second Xiangya hospital of central south univerity Changsha Hunan Recruiting

Other trials for the same condition

Environmental Determinants of Type 1 Diabetes Risk Recruiting
Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia Recruiting
Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers Recruiting
An Exploratory Study on the Prediction of Recurrence Risk of Bipolar Disorder Using Sentiment Analysis Technology Based on Multi-modal Feature Fusion Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06580860 on ClinicalTrials.gov ↗ ← All trials in China